title: Rapid infliximab infusions in pediatric inflammatory bowel disease.
abstract: The manufacturer of infliximab recommends infusion over 2 to 3 hours. In 16 children who received 133 standard 2- to 3-hour infusions, followed by fifty 1-hour infusions, chart review revealed a frequency of infusion reactions of 2% with both infusion protocols (3/133 and 1/50). The first reaction with the rapid infusion occurred in a patient who had experienced an identical reaction with the longer infusion, but was mistakenly not premedicated. Our data suggest rapid infusion over 1 hour in selected pediatric patients is safe and cost-effective. Compared with reported adult data, our data suggest similar or lower frequency of adverse events.
authors.affiliation: The Children's Hospital, Aurora, CO, USA.
authors.forename: Alyson R
authors.initials: AR
authors.lastname: Yeckes
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Hoffenberg
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous / Q000009:adverse effects*; D008297:Male; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab